The U.S. Food and Drug Administration approved Pfizer’s Xalkori (crizotinib) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase-positive.
AstraZeneca Plc’s cancer drug Imfinzi was approved in Europe and Britain for a spaced-out regimen in a common type of lung cancer to help reduce the frequency of hospital visits while continuing treatment.
BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.
Amgen is partnering with Ann Arbor, Michigan-based EVOQ Therapeutics for a license and collaboration deal to discover and develop drugs for autoimmune disorders.
At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”
Roche presented updated data confirming the Swiss drugmaker’s immunotherapy Tecentriq, used in combination with Avastin, substantially improves overall survival in people with the most common form of liver cancer.
Calithera Biosciences reported that the company’s CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.
Drugmakers agreed to cut prices by around 50% on average for more than 100 medicines in order to have them included in China’s state medical insurance scheme from March, potentially heralding a massive leap in sales.
An independent Data Monitoring Committee reviewed Bristol Myers Squibb’s CheckMate -548 Phase III trial of Opdivo (nivolumab) plus current standard of care in patients with newly diagnosed glioblastoma multiforme with 06-methylguanine-DNA methyltransferase promoter methylation following surgical resection of the tumor, and indicated the study would not meet the primary endpoint of overall survival.
